share_log

Walgreens Boots Alliance | 10-Q: Q3 2024 Earnings Report

Walgreens Boots Alliance | 10-Q: Q3 2024 Earnings Report

沃爾格林-聯合博姿 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/06/27 15:05

Moomoo AI 已提取核心訊息

Walgreens Boots Alliance reported Q3 FY2024 net earnings of $344 million, a 190.8% increase from $118 million in the year-ago quarter. Operating income improved to $111 million from a loss of $477 million, driven by cost savings initiatives and improved U.S. Healthcare segment profitability. Sales grew 2.6% to $36.4 billion, with U.S. Retail Pharmacy sales up 2.3% to $28.5 billion.The company's U.S. Healthcare segment showed significant improvement, narrowing its operating loss to $220 million from $522 million year-over-year. International segment sales increased 2.8% to $5.7 billion, with Boots UK comparable retail sales growing 6.0%. The company maintained its pharmacy market leadership with 306.4 million prescriptions filled, up 0.5% from the previous year.Looking ahead, Walgreens faces challenges including a softer U.S. retail environment and increased reimbursement pressure. The company reduced its quarterly dividend by 48% to strengthen its balance sheet and announced plans to acquire prescription files for up to $375 million. Management continues to focus on cost management and strategic initiatives to improve operational efficiency.
Walgreens Boots Alliance reported Q3 FY2024 net earnings of $344 million, a 190.8% increase from $118 million in the year-ago quarter. Operating income improved to $111 million from a loss of $477 million, driven by cost savings initiatives and improved U.S. Healthcare segment profitability. Sales grew 2.6% to $36.4 billion, with U.S. Retail Pharmacy sales up 2.3% to $28.5 billion.The company's U.S. Healthcare segment showed significant improvement, narrowing its operating loss to $220 million from $522 million year-over-year. International segment sales increased 2.8% to $5.7 billion, with Boots UK comparable retail sales growing 6.0%. The company maintained its pharmacy market leadership with 306.4 million prescriptions filled, up 0.5% from the previous year.Looking ahead, Walgreens faces challenges including a softer U.S. retail environment and increased reimbursement pressure. The company reduced its quarterly dividend by 48% to strengthen its balance sheet and announced plans to acquire prescription files for up to $375 million. Management continues to focus on cost management and strategic initiatives to improve operational efficiency.
沃爾格林-聯合博姿（WBA）報告了截至2024年5月31日的第三季度財務業績。公司交易應收賬款增至48億美元，較之前的截至2023年8月31日的43億美元有所增加。其他應收賬款，主要來自供應商和製造商，在同一時期也增加到12億美元，而去年同期爲11億美元。該季度的折舊及攤銷費用總額爲6.07億美元，略高於去年同期的5.98億美元。九個月內，這些費用達到了18.37億美元，而去年同期爲16.52億美元。物業、廠房和設備的累計折舊及攤銷達到135億美元，而之前爲130億美元。現金及現金等價物從739億美元降至7.03億美元，而總現金、現金等價物及受限現金爲7.4億美元，低於856億美元。可贖回的非控股權益從去年的1.6億美元略有增加到1.73億美元。公司的基本報表顯示了穩定的業績，應收賬款和折舊費用適度增加，而現金儲備略有減少。
沃爾格林-聯合博姿（WBA）報告了截至2024年5月31日的第三季度財務業績。公司交易應收賬款增至48億美元，較之前的截至2023年8月31日的43億美元有所增加。其他應收賬款，主要來自供應商和製造商，在同一時期也增加到12億美元，而去年同期爲11億美元。該季度的折舊及攤銷費用總額爲6.07億美元，略高於去年同期的5.98億美元。九個月內，這些費用達到了18.37億美元，而去年同期爲16.52億美元。物業、廠房和設備的累計折舊及攤銷達到135億美元，而之前爲130億美元。現金及現金等價物從739億美元降至7.03億美元，而總現金、現金等價物及受限現金爲7.4億美元，低於856億美元。可贖回的非控股權益從去年的1.6億美元略有增加到1.73億美元。公司的基本報表顯示了穩定的業績，應收賬款和折舊費用適度增加，而現金儲備略有減少。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    SunLink Health Systems
    SSY
    -- 0.900
    High Tide
    HITI
    -- 2.350
    Wellgistics Health
    WGRX
    -- 2.670
    沃爾格林-聯合博姿
    WBA
    -- 11.205
    PetMed Express
    PETS
    -- 4.020
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    科技巨頭財報季如火如荼，英偉達壓軸會表現如何？
    週四， $亞馬遜 (AMZN.US)$ 該公司報告第四季度調整後每股收益爲1.86美元，高於1.50美元的預期，營業收入爲1877.9亿美元，高於1873.2亿美元的預期。公司預測下一季度營收將低於華爾街的預期，預計本季度最多爲1550亿美元，而分析師們希望達到1580亿美元。 展开
    亞馬遜收益預覽：通過猜測開盤價格獲得獎勵！